CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CEP89 (ImmuneEditome ID:84902)

1. Gene summary of enriched editing regions for CEP89

check button Gene summary
Gene informationGene symbol

CEP89

Gene ID

84902

GeneSynonymsCCDC123|CEP123
GeneCytomap

19q13.11

GeneTypeprotein-coding
GeneDescriptioncentrosomal protein of 89 kDa|centrosomal protein 123|centrosomal protein 89kDa|coiled-coil domain containing 123|coiled-coil domain-containing protein 123, mitochondrial
GeneModificationdate20230329
UniprotIDQ96ST8;A0A0C4DGP8;K7EPU8;K7EJF0;A0A087WXS8
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:32877635-32878959:-ENST00000586628.2ENSG00000121289.16CEP89ncRNA_exonicAluJr,AluSq2chr19:32877635-32878959:-.alignment
chr19:32970388-32971623:-ENST00000591863.1ENSG00000121289.16CEP89exonicAluSx1,L2c,AluJo,AluJrchr19:32970388-32971623:-.alignment


Top

2. Tumor-specific enriched editing regions for CEP89


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:32877635-32878959:-KIRCEER3.2843e-03image
chr19:32877635-32878959:-THCAEER3.3188e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:32877635-32878959:-HNSCCliEER1.7157e-022.4709e-02-0.2008image
chr19:32970388-32971623:-KIRCPathEER3.9497e-035.3923e-030.1392image
ENSG00000121289.16,CEP89KIRPCliEAG3.1179e-031.7245e-020.1740image
chr19:32877635-32878959:-KIRPCliEER7.3719e-053.3588e-030.3076image
chr19:32970388-32971623:-THCAPathEER7.2514e-034.6584e-030.1730image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:32970388-32971623:-CHOLEER6.0196e-041.8491e-033.1778e+15image
chr19:32970388-32971623:-ESCAEER3.1696e-033.6442e-033.8478e+03image
chr19:32970388-32971623:-UCECEER4.8065e-022.2723e-021.8629e+03image

Top

3. Enriched editing regions and immune related genes for CEP89


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:32970388-32971623:-GBMEERENSG00000110060,PUS3-0.46491.1774e-054.6839e-07-0.4079imageNBUD13;CNBP;CPSF6;CSTF2T;EIF4A3;FBL;FMR1;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PRPF8;RBM10;RBM47;SND1;SRSF1;TAF15;TIA1;U2AF1;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_MYOGENESIS
chr19:32970388-32971623:-GBMEERENSG00000101146,RAE1-0.46381.5175e-053.3348e-07-0.4127imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX42;EIF4A3;EWSR1;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;MSI2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM47;SLTM;SND1;SRSF1;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;XRN2NAMonocytesGSVA_HALLMARK_DNA_REPAIR
chr19:32970388-32971623:-GBMEERENSG00000196812,ZSCAN16-0.44603.2061e-055.9840e-07-0.4044imageNACIN1;BUD13;EIF4A3;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;PRPF8;RANGAP1;RBFOX2;SRSF1;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_COAGULATION
chr19:32970388-32971623:-GBMEERENSG00000197006,METTL9-0.44673.9480e-053.0542e-07-0.4139imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX42;EIF4A3;EWSR1;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;MSI2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM47;SLTM;SND1;SRSF1;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;XRN2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:32970388-32971623:-GBMEERENSG00000163002,NUP35-0.44215.1318e-052.6689e-07-0.4158imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX42;EIF4A3;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;MSI2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM47;SLTM;SND1;SRSF1;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;XRN2NAT_cells_follicular_helperGSVA_HALLMARK_MYOGENESIS
chr19:32970388-32971623:-GBMEERENSG00000159055,MIS18A-0.43467.6552e-056.8378e-07-0.4025imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;EIF4A3;EWSR1;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;MSI2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM47;SLTM;SND1;SRSF1;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;XRN2NAMonocytesGSVA_HALLMARK_E2F_TARGETS
chr19:32970388-32971623:-GBMEERENSG00000131043,AAR2-0.42948.0350e-055.5444e-07-0.4055imageNBUD13;CNBP;CPSF6;CSTF2T;DDX42;EIF4A3;EWSR1;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PRPF8;RANGAP1;RBFOX2;RBM10;SLTM;SND1;SRSF1;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2NAMonocytesGSVA_HALLMARK_MYC_TARGETS_V2
chr19:32970388-32971623:-GBMEERENSG00000137513,NARS2-0.42221.2750e-042.4550e-07-0.4169imageNACIN1;BUD13;CNBP;CSTF2T;EIF4A3;EWSR1;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;MSI2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM47;SLTM;SND1;SRSF1;SRSF9;TAF15;TIA1;U2AF1;U2AF2;XRN2NAT_cells_follicular_helperGSVA_HALLMARK_MYOGENESIS
chr19:32970388-32971623:-GBMEERENSG00000256234,RP11-283G6.40.26024.1100e-023.5511e-070.4118imageNCSTF2T;EIF4A3;EWSR1;FBL;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2NAPlasma_cellsGSVA_HALLMARK_G2M_CHECKPOINT

More results



Top

4. Enriched editing regions and immune related splicing for CEP89


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:32970388-32971623:-
ESCAEERESENSG00000203705.6chr1212807735:212807848:212812247:212812328:212815012:212815175-0.28102.8904e-021.4965e-05-0.4017imageNBUD13;CNBP;CPSF6;CSTF2T;DDX42;EIF4A3;EWSR1;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PRPF8;RBFOX2;RBM10;SLTM;SND1;SRSF1;SRSF9;TAF15;TRA2A;U2AF1;U2AF2;XRN2NA
chr19:32970388-32971623:-
ESCAEERESENSG00000085276.13chr3169102059:169102226:169107925:169107952:169112786:169112874-0.34983.0567e-023.4143e-06-0.4538imageNACIN1;CNBP;CPSF6;CSTF2T;EIF4A3;EWSR1;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PRPF8;RBFOX2;RBM10;RBM47;SND1;SRSF1;SRSF9;TAF15;TIA1;U2AF2;XRN2MECOMEosinophilsGSVA_HALLMARK_BILE_ACID_METABOLISM
chr19:32970388-32971623:-
ESCAEERIRENSG00000125149.7chr1667131988:67132525:67132878:67132911-0.22644.5873e-028.0573e-06-0.4490imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX42;EIF4A3;EWSR1;FBL;FMR1;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PRPF8;RANGAP1;RBFOX2;RBM10;RBM47;SLTM;SND1;SRSF1;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;XRN2NAT_cells_CD4_naiveGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
ENSG00000121289.16,CEP89
TGCTEAGESENSG00000069122.14chr646853733:46854071:46854714:46854781:46855973:468560580.28502.8203e-027.0642e-060.4633imageNADAR;CELF2;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FUS;HNRNPA1;HNRNPL;NOP56;RBM10;SRSF1;SRSF3;TAF15;TARBP2;U2AF2;UPF1;YTHDC1NAB_cells_naiveGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
ENSG00000121289.16,CEP89
TGCTEAGESENSG00000171634.12chr1767928354:67928601:67928958:67929120:67929335:67929487-0.39372.6080e-034.5291e-06-0.4180imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZFP36;ZNF184NAMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000121289.16,CEP89
TGCTEAGIRENSG00000168890.9chr285601883:85602064:85602606:856026540.35344.8823e-034.1061e-050.4019imageNAUH;BUD13;CSTF2T;DDX3X;DDX42;DDX54;EIF4A3;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LIN28B;LSM11;MOV10;NOP58;PCBP2;PRPF8;RBFOX2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
ENSG00000121289.16,CEP89
TGCTEAGESENSG00000152818.14chr6144820881:144821018:144827347:144827386:144827610:144827676-0.36532.8528e-031.1605e-05-0.4250imageNACIN1;ADAR;AIFM1;ALYREF;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000121289.16,CEP89
TGCTEAGIRENSG00000102901.8chr1667829764:67831324:67831575:67831612-0.20922.0900e-022.3136e-07-0.4920imageNACIN1;ADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;ZNF184NADendritic_cells_activated
ENSG00000121289.16,CEP89
TGCTEAGA5ENSG00000170889.9chr1954207397:54207522:54206552:54206724:54206552:54207074-0.12857.2655e-036.6427e-07-0.4423imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184NAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000121289.16,CEP89
TGCTEAGMEXENSG00000119185.8chr29418625:9418732:9420034:9420100:9422478:9422696:9423372:94234800.31827.8985e-036.7612e-050.4095imageNACIN1;ADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184ITGB1BP1Macrophages_M2GSVA_HALLMARK_ANGIOGENESIS

More results



Top

5. Enriched editing regions and immune infiltration for CEP89


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000121289.16,CEP89ACCEAGT_cells_CD4_naive2.4803e-020.3052image
chr19:32970388-32971623:-BLCAEERMast_cells_activated2.3189e-02-0.1430image
ENSG00000121289.16,CEP89BLCAEAGMacrophages_M11.7424e-020.1258image
chr19:32970388-32971623:-BRCAEERT_cells_CD4_naive2.6461e-020.0739image
ENSG00000121289.16,CEP89BRCAEAGMacrophages_M27.6923e-030.0824image
ENSG00000121289.16,CEP89CESCEAGMacrophages_M14.8932e-020.1206image
ENSG00000121289.16,CEP89CHOLEAGMast_cells_resting3.2836e-020.3724image
ENSG00000121289.16,CEP89COADEAGT_cells_CD84.1260e-02-0.1658image
chr19:32877635-32878959:-ESCAEERB_cells_naive1.0958e-020.2586image
chr19:32970388-32971623:-ESCAEERB_cells_memory1.9143e-020.2154image
ENSG00000121289.16,CEP89ESCAEAGB_cells_naive1.3527e-020.2019image
chr19:32877635-32878959:-GBMEEREosinophils9.7206e-030.2392image
chr19:32970388-32971623:-GBMEERPlasma_cells1.7414e-050.3520image
ENSG00000121289.16,CEP89GBMEAGPlasma_cells8.4645e-030.2075image
chr19:32970388-32971623:-HNSCEERDendritic_cells_resting8.5821e-030.1760image
ENSG00000121289.16,CEP89HNSCEAGT_cells_CD4_naive4.0219e-02-0.1091image
chr19:32970388-32971623:-KIRCEERT_cells_CD4_memory_activated7.0803e-050.2308image
ENSG00000121289.16,CEP89KIRCEAGDendritic_cells_resting1.1462e-020.1346image
chr19:32877635-32878959:-KIRPEERNK_cells_resting5.4180e-040.2960image
chr19:32970388-32971623:-KIRPEERT_cells_regulatory_(Tregs)4.1036e-020.1542image
ENSG00000121289.16,CEP89KIRPEAGNK_cells_resting1.2814e-020.1513image
chr19:32877635-32878959:-LGGEERMonocytes8.6316e-030.1675image
chr19:32970388-32971623:-LGGEERMacrophages_M03.2147e-05-0.2288image
ENSG00000121289.16,CEP89LGGEAGMacrophages_M21.9538e-03-0.1442image
chr19:32877635-32878959:-LUADEERMacrophages_M11.1062e-02-0.2141image
ENSG00000121289.16,CEP89LUADEAGT_cells_gamma_delta3.9434e-020.1045image
chr19:32877635-32878959:-LUSCEERNK_cells_resting3.5844e-030.2166image
chr19:32970388-32971623:-LUSCEERT_cells_regulatory_(Tregs)6.1860e-030.1440image
ENSG00000121289.16,CEP89LUSCEAGDendritic_cells_activated7.2420e-040.1651image
chr19:32970388-32971623:-MESOEERMast_cells_resting4.7488e-02-0.2685image
chr19:32970388-32971623:-OVEERDendritic_cells_activated4.0627e-030.1888image
ENSG00000121289.16,CEP89OVEAGB_cells_memory4.2026e-020.1203image
chr19:32970388-32971623:-PCPGEERMast_cells_resting2.5543e-02-0.2436image
ENSG00000121289.16,CEP89PCPGEAGNeutrophils4.2869e-030.2304image
chr19:32970388-32971623:-PRADEERB_cells_memory5.2087e-030.1432image
ENSG00000121289.16,CEP89PRADEAGB_cells_memory1.4903e-020.1120image
chr19:32970388-32971623:-READEERMast_cells_resting2.9367e-020.3537image
ENSG00000121289.16,CEP89READEAGDendritic_cells_activated1.6119e-02-0.3045image
chr19:32877635-32878959:-SARCEERMacrophages_M11.4836e-020.2220image
chr19:32970388-32971623:-SARCEERNeutrophils4.5724e-02-0.1483image
chr19:32877635-32878959:-SKCMEERT_cells_follicular_helper2.8155e-030.2340image
chr19:32970388-32971623:-SKCMEERT_cells_CD81.8441e-060.2550image
ENSG00000121289.16,CEP89SKCMEAGT_cells_CD81.1294e-040.1884image
chr19:32877635-32878959:-STADEERT_cells_follicular_helper1.2013e-020.2000image
chr19:32970388-32971623:-STADEERNeutrophils5.5418e-030.1945image
ENSG00000121289.16,CEP89STADEAGMast_cells_resting1.1014e-030.1940image
chr19:32970388-32971623:-TGCTEERMacrophages_M21.6073e-05-0.4469image
ENSG00000121289.16,CEP89TGCTEAGMacrophages_M21.7382e-03-0.2877image
chr19:32970388-32971623:-THCAEERT_cells_regulatory_(Tregs)2.0904e-030.1865image
ENSG00000121289.16,CEP89THCAEAGEosinophils4.6488e-02-0.0905image
ENSG00000121289.16,CEP89THYMEAGT_cells_gamma_delta1.9124e-030.2967image
chr19:32970388-32971623:-UCECEERT_cells_CD85.6699e-030.2803image
chr19:32877635-32878959:-UCSEERMacrophages_M12.6340e-020.4052image


Top

6. Enriched editing regions and immune gene sets for CEP89


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000121289.16,CEP89ACCGSVA_HALLMARK_SPERMATOGENESISEAG1.6755e-020.3242image
ENSG00000121289.16,CEP89BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.0182e-030.1732image
chr19:32970388-32971623:-BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.0440e-050.2556image
ENSG00000121289.16,CEP89BRCAGSVA_HALLMARK_ADIPOGENESISEAG4.9340e-070.1547image
chr19:32970388-32971623:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.3848e-060.1509image
chr19:32877635-32878959:-BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER3.1695e-03-0.1056image
ENSG00000121289.16,CEP89CESCGSVA_HALLMARK_HEME_METABOLISMEAG8.4676e-030.1608image
ENSG00000121289.16,CEP89CHOLGSVA_HALLMARK_SPERMATOGENESISEAG2.6599e-020.3858image
chr19:32970388-32971623:-CHOLGSVA_HALLMARK_SPERMATOGENESISEER4.4628e-020.3632image
ENSG00000121289.16,CEP89ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4617e-02-0.1997image
chr19:32970388-32971623:-ESCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER1.6923e-02-0.2195image
chr19:32877635-32878959:-ESCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.5513e-020.2046image
chr19:32970388-32971623:-GBMGSVA_HALLMARK_MYC_TARGETS_V1EER2.2298e-04-0.3051image
chr19:32877635-32878959:-GBMGSVA_HALLMARK_MITOTIC_SPINDLEEER3.0137e-03-0.2731image
ENSG00000121289.16,CEP89GBMGSVA_HALLMARK_E2F_TARGETSEAG8.1723e-05-0.3063image
ENSG00000121289.16,CEP89HNSCGSVA_HALLMARK_COAGULATIONEAG3.2787e-030.1559image
chr19:32970388-32971623:-HNSCGSVA_HALLMARK_SPERMATOGENESISEER9.6706e-04-0.2200image
chr19:32877635-32878959:-HNSCGSVA_HALLMARK_HYPOXIAEER1.2032e-020.2222image
ENSG00000121289.16,CEP89KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.6214e-030.1473image
chr19:32877635-32878959:-KIRCGSVA_HALLMARK_ANGIOGENESISEER3.2176e-02-0.1664image
chr19:32970388-32971623:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.8569e-040.2112image
ENSG00000121289.16,CEP89KIRPGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.1697e-03-0.1790image
chr19:32877635-32878959:-KIRPGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER3.4793e-03-0.2516image
chr19:32970388-32971623:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER1.9154e-03-0.2323image
chr19:32877635-32878959:-LGGGSVA_HALLMARK_MTORC1_SIGNALINGEER2.1438e-04-0.2344image
chr19:32970388-32971623:-LGGGSVA_HALLMARK_G2M_CHECKPOINTEER5.0945e-08-0.2970image
ENSG00000121289.16,CEP89LGGGSVA_HALLMARK_DNA_REPAIREAG2.4904e-05-0.1954image
chr19:32970388-32971623:-LIHCGSVA_HALLMARK_DNA_REPAIREER3.8845e-02-0.3057image
ENSG00000121289.16,CEP89LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG9.3637e-030.2501image
chr19:32877635-32878959:-LUADGSVA_HALLMARK_ANGIOGENESISEER5.8928e-030.2316image
ENSG00000121289.16,CEP89LUADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.7651e-020.1203image
chr19:32970388-32971623:-LUADGSVA_HALLMARK_MITOTIC_SPINDLEEER2.0678e-02-0.1299image
chr19:32877635-32878959:-LUSCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.4344e-020.1505image
ENSG00000121289.16,CEP89LUSCGSVA_HALLMARK_SPERMATOGENESISEAG4.5273e-04-0.1712image
chr19:32970388-32971623:-LUSCGSVA_HALLMARK_SPERMATOGENESISEER1.3507e-05-0.2271image
chr19:32970388-32971623:-MESOGSVA_HALLMARK_ADIPOGENESISEER3.8795e-02-0.2795image
chr19:32877635-32878959:-OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.4298e-03-0.2021image
chr19:32970388-32971623:-OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.3742e-04-0.2343image
ENSG00000121289.16,CEP89OVGSVA_HALLMARK_SPERMATOGENESISEAG1.5006e-04-0.2223image
ENSG00000121289.16,CEP89PCPGGSVA_HALLMARK_HEME_METABOLISMEAG9.0706e-040.2664image
ENSG00000121289.16,CEP89PRADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.1129e-020.0992image
chr19:32970388-32971623:-PRADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER3.2895e-03-0.1506image
chr19:32877635-32878959:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER2.2444e-02-0.1634image
chr19:32970388-32971623:-READGSVA_HALLMARK_MYC_TARGETS_V1EER3.7193e-02-0.3393image
ENSG00000121289.16,CEP89SARCGSVA_HALLMARK_DNA_REPAIREAG2.6180e-03-0.1918image
chr19:32877635-32878959:-SARCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.5373e-020.2208image
chr19:32970388-32971623:-SARCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.7235e-05-0.3127image
chr19:32877635-32878959:-SKCMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER3.3295e-020.1679image
chr19:32970388-32971623:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1052e-060.2602image
ENSG00000121289.16,CEP89SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4926e-040.1851image
chr19:32970388-32971623:-STADGSVA_HALLMARK_MITOTIC_SPINDLEEER8.9651e-03-0.1834image
ENSG00000121289.16,CEP89STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.4368e-03-0.1743image
ENSG00000121289.16,CEP89TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.3831e-050.3658image
chr19:32970388-32971623:-TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.7208e-040.3943image
chr19:32877635-32878959:-THCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.7417e-04-0.2026image
ENSG00000121289.16,CEP89THCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.7322e-040.1646image
chr19:32970388-32971623:-THCAGSVA_HALLMARK_COAGULATIONEER5.6875e-040.2084image
ENSG00000121289.16,CEP89THYMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1011e-030.3113image
chr19:32970388-32971623:-UCECGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.2844e-020.2180image
chr19:32877635-32878959:-UCSGSVA_HALLMARK_APOPTOSISEER1.6537e-020.4341image
chr19:32970388-32971623:-UCSGSVA_HALLMARK_DNA_REPAIREER6.2128e-030.4108image
ENSG00000121289.16,CEP89UVMGSVA_HALLMARK_APICAL_JUNCTIONEAG1.0231e-020.3435image


Top

7. Enriched editing regions and drugs for CEP89


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000121289.16,CEP89ACCAUY922EAG3.7815e-02-0.2834image
chr19:32877635-32878959:-BLCAGW.441756EER2.3914e-02-0.2258image
ENSG00000121289.16,CEP89BLCADMOGEAG2.0111e-03-0.1629image
chr19:32970388-32971623:-BLCAEHT.1864EER4.6340e-050.2536image
ENSG00000121289.16,CEP89BRCALapatinibEAG3.6041e-05-0.1279image
chr19:32970388-32971623:-BRCAABT.263EER9.0296e-040.1106image
chr19:32877635-32878959:-BRCALapatinibEER6.0546e-04-0.1231image
ENSG00000121289.16,CEP89CESCBIBW2992EAG1.7986e-02-0.1450image
chr19:32970388-32971623:-CESCAZD.2281EER8.1992e-03-0.2010image
ENSG00000121289.16,CEP89CHOLCyclopamineEAG4.5044e-030.4820image
chr19:32970388-32971623:-CHOLCyclopamineEER3.7609e-020.3751image
ENSG00000121289.16,CEP89DLBCAMG.706EAG1.0814e-02-0.5320image
ENSG00000121289.16,CEP89ESCABMS.536924EAG5.7263e-03-0.2253image
chr19:32877635-32878959:-ESCALapatinibEER1.2191e-03-0.3339image
chr19:32970388-32971623:-ESCACGP.60474EER5.5727e-03-0.2537image
chr19:32970388-32971623:-GBMBI.2536EER2.2863e-060.3846image
chr19:32877635-32878959:-GBMBMS.708163EER2.4448e-02-0.2089image
ENSG00000121289.16,CEP89GBMBI.D1870EAG1.6367e-050.3335image
ENSG00000121289.16,CEP89HNSCDMOGEAG1.6650e-02-0.1272image
chr19:32970388-32971623:-HNSCBosutinibEER2.6741e-03-0.2006image
chr19:32877635-32878959:-HNSCCGP.60474EER2.5811e-02-0.1978image
chr19:32877635-32878959:-KIRCDasatinibEER6.8927e-030.2102image
ENSG00000121289.16,CEP89KIRCAS601245EAG3.3919e-030.1558image
chr19:32970388-32971623:-KIRCCGP.60474EER3.1254e-05-0.2415image
chr19:32877635-32878959:-KIRPAS601245EER7.5810e-050.3363image
ENSG00000121289.16,CEP89KIRPGSK.650394EAG2.9370e-040.2187image
chr19:32970388-32971623:-KIRPGSK.650394EER7.2067e-060.3310image
ENSG00000121289.16,CEP89LGGCisplatinEAG1.9455e-070.2400image
chr19:32970388-32971623:-LGGBI.2536EER3.3812e-100.3398image
chr19:32877635-32878959:-LGGEmbelinEER1.0533e-030.2081image
chr19:32970388-32971623:-LIHCGSK.650394EER2.4759e-030.4357image
ENSG00000121289.16,CEP89LIHCBleomycinEAG8.3653e-030.2598image
chr19:32970388-32971623:-LUADGDC0941EER9.8563e-03-0.1448image
ENSG00000121289.16,CEP89LUADGDC0941EAG3.9523e-03-0.1458image
chr19:32877635-32878959:-LUADEpothilone.BEER4.8852e-040.2909image
chr19:32970388-32971623:-LUSCAZD6244EER2.4221e-06-0.2455image
ENSG00000121289.16,CEP89LUSCGefitinibEAG7.7756e-06-0.2175image
ENSG00000121289.16,CEP89MESOJNK.9LEAG7.4708e-03-0.2988image
chr19:32970388-32971623:-MESOGW843682XEER2.6243e-020.2997image
chr19:32877635-32878959:-OVGefitinibEER2.1726e-03-0.2047image
chr19:32970388-32971623:-OVBIBW2992EER4.4681e-05-0.2657image
ENSG00000121289.16,CEP89OVBMS.509744EAG4.2126e-04-0.2072image
ENSG00000121289.16,CEP89PAADMG.132EAG2.4784e-020.1791image
ENSG00000121289.16,CEP89PCPGDMOGEAG1.0590e-07-0.4150image
chr19:32970388-32971623:-PCPGAxitinibEER6.6827e-030.2938image
ENSG00000121289.16,CEP89PRADAUY922EAG5.1022e-030.1287image
chr19:32970388-32971623:-PRADCyclopamineEER1.7369e-04-0.1943image
chr19:32877635-32878959:-PRADBMS.536924EER1.7415e-02-0.1701image
chr19:32970388-32971623:-READGemcitabineEER1.9490e-030.4866image
ENSG00000121289.16,CEP89READCamptothecinEAG7.3442e-030.3373image
chr19:32970388-32971623:-SARCGefitinibEER3.0984e-03-0.2181image
ENSG00000121289.16,CEP89SARCGefitinibEAG1.5871e-02-0.1543image
ENSG00000121289.16,CEP89SKCMAZD6244EAG1.0258e-03-0.1606image
chr19:32877635-32878959:-SKCMBicalutamideEER1.7200e-02-0.1876image
chr19:32970388-32971623:-SKCMCI.1040EER3.0999e-05-0.2236image
ENSG00000121289.16,CEP89STADAZD6244EAG3.7014e-02-0.1247image
chr19:32970388-32971623:-STADAICAREER1.1170e-02-0.1782image
chr19:32877635-32878959:-STADBMS.536924EER3.3829e-02-0.1695image
chr19:32970388-32971623:-TGCTBMS.754807EER8.2366e-040.3541image
ENSG00000121289.16,CEP89TGCTFTI.277EAG2.2451e-030.2810image
chr19:32877635-32878959:-THCAJNJ.26854165EER2.2535e-030.1775image
chr19:32970388-32971623:-THCAEmbelinEER6.7875e-090.3435image
ENSG00000121289.16,CEP89THCACEP.701EAG2.3144e-050.1911image
ENSG00000121289.16,CEP89THYMCMKEAG3.2508e-020.2069image
chr19:32970388-32971623:-UCECKU.55933EER8.8854e-04-0.3338image
chr19:32877635-32878959:-UCSAZD7762EER1.7642e-02-0.4302image
chr19:32970388-32971623:-UCSFH535EER1.0616e-030.4821image
ENSG00000121289.16,CEP89UCSBMS.509744EAG3.9735e-02-0.2757image
ENSG00000121289.16,CEP89UVMBleomycinEAG7.5879e-030.3563image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType